INOVIQ Ltd (ASX:IIQ)

October marks Breast Cancer Awareness Month. INOVIQ Ltd (ASX:IIQ) is developing better diagnostics and therapeutics for earlier detection and treatment of breast cancer. Show your support by wearing pink and starting important conversations with your loved ones about early detection. To help in the fight against breast cancer, visit https://lnkd.in/etpVpWV #BreastCancerAwarenessMonth #ThinkPink #EarlyDetectionSavesLives #Exosomes #Diagnostics #Therapeutics

INOVIQ Ltd (ASX:IIQ) is pleased to welcome Mary Harney as a Non-Executive Director, effective from 1 October 2024. Mary is an experienced Non-Executive Director and Chief Executive, bringing a wealth of expertise in applied life science research, biopharmaceutical regulatory affairs, and commercialisation. To read the full announcement go to https://lnkd.in/gRtnfyKm #INOVIQ #BoardAnnouncement #Biotech #Diagnostics #Therapeutics #SmallCap 

MST Financial released an update note on INOVIQ Ltd (ASX:IIQ) FY2024 results and highlights: ✔ Promega distribution agreement for EXO-NET expands global reach and expected to drive future revenues. ✔ NEURO-NET validated for isolating brain-derived exosomes in Alzheimer’s Disease. ✔ Breast & ovarian cancer detection and monitoring tests progress towards commercialisation. ✔ In vitro POC for exosome therapeutics to target and kill breast cancer. Access the full report here: https://lnkd.in/gKhvvmBn #Biotech #SmallCap #Diagnositics #Therapeutics #exosomes #MSTAccess #research #cancerresearch

Daffodil Day raises awareness and much-needed funds for cancer research. At INOVIQ Ltd (ASX:IIQ) we are committed to saving lives through diagnostics and therapeutics cancer research.   To find out more visit https://lnkd.in/dfckUXF    #DaffodilDay #CancerResearch #INOVIQ #Diagnositcs #Therapeutics

INOVIQ Ltd (ASX:IIQ) is pleased to announce that it has further validated its NEURO-NET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD). Initial validation studies in PD, highlight the utility of NEURO-NET™: ✔ NEURO-NET™ enriches known protein biomarkers of neurodegenerative disease by 5-8 times, greatly increasing the potential for early detection of Parkinson’s. ✔ Analysis identified over 200 proteins that were decreased or increased in PD patients when compared to normal healthy individuals. To find out more go to: https://lnkd.in/g_GwMPGC #NEURONET #Parkinsons #exosomes #research #INOVIQ #validationstudy #diagnostics #therapeutics #Biotech

MST Financial released an update note on INOVIQ Ltd (ASX:IIQ) fuelling key FY25 priorities: ✔ Diverse portfolio of cutting-edge technology platforms and products ✔ Collaboration with UQ to develop exosome-based ovarian cancer screening test ✔ SubB2M Platform delivers promising results in ovarian and breast cancers, with potential to supercharge current tests for cancer monitoring Access the full report here:  https://lnkd.in/gf92ph3D #Biotech #SmallCap #Diagnositics #Therapeutics #exosomes #MSTAccess #research #cancerresearch

INOVIQ Ltd (ASX:IIQ) has released its June quarterly business update and Appendix 4C highlighting increasing revenue from its research tools, progress on its cancer diagnostic and therapeutic programs and a solid cash balance of $9.233m at 30 June 2024. Go to https://lnkd.in/gFtuPdWn to read more. #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Exosomes #Therapeutics #Diagnostics #CancerResearch #LifeSciences

INOVIQ Ltd (ASX:IIQ) is pleased to announce the successful completion of the share purchase plan (SPP) with applications accepted for A$2.379 million. ✔ IIQ successfully completed its SPP with applications totalling A$7.29m, exceeding its target of A$2m. ✔ Directors accepted allocations to the maximum of A$2.379m, with scale back on a pro-rata basis. ✔ Total capital raised of A$9.379m under the SPP and recent placement (A$7m) to institutional and sophisticated investors. ✔ Investors in the Placement & SPP received one free quoted option for every two new Shares issued with an exercise price of $1.00 and expiry of 8 July 2026. ✔ INOVIQ now has a pro forma cash balance of approximately A$14.489 million. ✔ Funds will be used to advance the commercialisation of EXO-NET research tools and SubB2M cancer monitoring tests, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics. Go to https://lnkd.in/gQ8JhHTR to read more. #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Exosomes #Therapeutics #Diagnostics #CancerResearch #LifeSciences

INOVIQ Ltd (ASX:IIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease. Initial analytical and clinical validation studies showed: ✔ Exosomes isolated from blood using NEURO-NET contain proteins known to be expressed by brain cells; ✔ NEURO-NET was superior to other commercially available methods tested in isolating brain-derived exosomes from blood; ✔ NEURO-NET enabled the identification of known Alzheimer’s biomarkers in exosomes that could not be detected by other methods; ✔ Analysis of NEURO-NET-captured exosomes identified more than 200 proteins that were differentially expressed in Alzheimer’s patients when compared with healthy individuals. To find out more go to: https://lnkd.in/gTep2tzk #INOVIQ #NEURONET #Alzheimers #Exosomes #Therapeutics #Diagnostics #Research

INOVIQ Ltd (ASX:IIQ) is pleased to announce that it has successfully completed an A$7 million placement to institutional and sophisticated investors at A$0.50 per share. Funds raised will be used to advance commercialisation of EXO-NET® research tools and SubB2M diagnostics, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics, enabling the Company to progress its pipeline and bring new products to market. Over the next 12-months, INOVIQ expects to achieve the following milestones: ◼ Revenue growth from sales of EXO-NET exosome isolation tools (through our Promega partnership and direct sales/services); ◼ Exosome diagnostic biomarker validation for ovarian cancer; ◼ Exosome diagnostic development agreement (collaborator/partner); ◼ Exosome therapeutic in vitro data for breast cancer; and ◼ Commercial partner for SubB2M test for monitoring breast cancer. To read the announcement go to: https://lnkd.in/gRSjY9mw To read the investor presentation go to: https://lnkd.in/gx-RWae7 #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Therapeutics #Diagnostics #CancerResearch #LifeSciences